Contractility Measurements of Human Uterine Smooth Muscle to Aid Drug Development



Arrowsmith, Sarah, Keov, Peter, Muttenthaler, Markus and Gruber, Christian W
(2018) Contractility Measurements of Human Uterine Smooth Muscle to Aid Drug Development. JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2018 (131). 56639-.

[img] Text
jove accepted.docx - Author Accepted Manuscript

Download (55kB)

Abstract

Discovery and characterization of novel pharmaceutical compounds or biochemical probes rely on robust and physiologically relevant assay systems. We describe methods to measure ex vivo myometrium contractility. This assay can be used to investigate factors and molecules involved in the modulation of myometrial contraction and to determine their excitatory or inhibitory actions, and hence their therapeutic potential in vivo. Biopsies are obtained from women undergoing cesarean section delivery with informed consent. Fine strips of myometrium are dissected, clipped and attached to a force transducer within 1 mL organ baths superfused with physiological saline solution at 37 °C. Strips develop spontaneous contractions within 2-3 h under set tension and remain stable for many hours (>6 h). Strips can also be stimulated to contract such as by the endogenous hormones, oxytocin and vasopressin, which cause concentration-dependent modulation of contraction frequency, force and duration, to more closely resemble contractions in labor. Hence, the effect of known and novel drug leads can be tested on spontaneous and agonist-induced contractions. This protocol specifically details how this assay can be used to determine the potency of known and novel agents by measuring their effects on various parameters of human myometrial contraction. We use the oxytocin- and V1a receptor antagonists, atosiban and SR49059 as examples of known compounds which inhibit oxytocin- and vasopressin-induced contractions, and demonstrate how this method can be used to complement and validate pharmacological data obtained from cell-based assays to aid drug development. The effects of novel agonists in comparison to oxytocin and vasopressin can also be characterized. Whilst we use the example of the oxytocin/ vasopressin system, this method can also be used to study other receptors and ion channels that play a role in uterine contraction and relaxation to advance the understanding of human uterine physiology and pathophysiology.

Item Type: Article
Uncontrolled Keywords: Medicine, Issue 131, Physiology, pharmacology, myometrium, human uterus, contraction, organ bath, peptide, oxytocin, vasopressin, drug discovery
Depositing User: Symplectic Admin
Date Deposited: 27 Mar 2018 06:13
Last Modified: 15 Mar 2024 08:09
DOI: 10.3791/56639
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3019508